Repositioning Candidate Details
| Candidate ID: | R0451 |
| Source ID: | DB06586 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Cetilistat |
| Synonyms: | |
| Molecular Formula: | C25H39NO3 |
| SMILES: | CCCCCCCCCCCCCCCCOC1=NC2=C(C=C(C)C=C2)C(=O)O1 |
| Structure: |
|
| DrugBank Description: | Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes. |
| CAS Number: | 282526-98-1 |
| Molecular Weight: | 401.5821 |
| DrugBank Indication: | Investigated for use/treatment in obesity. |
| DrugBank Pharmacology: | |
| DrugBank MoA: | Cetilistat is a gastrointestinal lipase inhibitor that blocks fat digestion and absorption, leading to reduced energy intake, and thus weight loss. It is distinct from most other anti-obesity agents as it does not act on the brain to reduce appetite, but acts peripherally. The compound remains in the gastrointestinal tract with no significant absorption into the body. |
| Targets: | Pancreatic triacylglycerol lipase |
| Inclusion Criteria: |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|